RxDoctor Payments Data

David Rose, MD

Internal Medicine · Glen Burnie, MDNPI 1780697482

Payments from drug & device makers

$313in general payments, 2019–2025

Across 16 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$102
  • Lilly USA, LLC$81
  • AstraZeneca$57
  • Sumitomo Pharma America, Inc.$19
  • Boehringer Ingelheim$19
  • Lundbeck LLC$18
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$313 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$201,283
Medicare patients
221
Services billed
2,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$234,620
EliquisApixaban40$65,966
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$30,201
JardianceEmpagliflozin21$23,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$21,127
ProliaDenosumab12$20,493
XareltoRivaroxaban13$20,288
Repatha SureclickEvolocumab23$13,271
Potassium Chloride296$11,773
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,695
AliskirenAliskiren Hemifumarate31$11,204
Eplerenone127$11,159
Breo ElliptaFluticasone/Vilanterol14$8,975
Verapamil SrVerapamil Hcl47$8,569
Dexlansoprazole DrDexlansoprazole17$7,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$234,620223 claims
Boehringer IngelheimJardiance$19$23,19821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →